Increasing consumption of antibiotics during the COVID-19 pandemic: implications for patient health and emerging anti-microbial resistance

SS Malik, S Mundra - Antibiotics, 2022 - mdpi.com
The emergence of COVID-19 infection led to the indiscriminate use of antimicrobials without
knowing their efficacy in treating the disease. The gratuitous use of antibiotics for COVID-19 …

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

H Yousefi, L Mashouri, SC Okpechi, N Alahari… - Biochemical …, 2021 - Elsevier
The outbreak of a novel coronavirus (SARS-CoV-2) has caused a major public health
concern across the globe. SARS-CoV-2 is the seventh coronavirus that is known to cause …

[HTML][HTML] RETRACTED: Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate

A Pradelle, S Mainbourg, S Provencher, E Massy… - 2024 - Elsevier
Following publication, the Journal was made aware of readers' debate about this article. The
Journal received a number of Letters to the Editor and correspondence from readers. The …

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

PC Robinson, D Richards, HL Tanner… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic continues to wreak havoc on global health-care systems and to
claim an increasing number of lives. Although some treatments have shown promise …

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

TSC Hinks, L Cureton, R Knight, A Wang… - The Lancet …, 2021 - thelancet.com
Background The antibacterial, anti-inflammatory, and antiviral properties of azithromycin
suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate …

[HTML][HTML] Withania somnifera (L.) Dunal: opportunity for clinical repurposing in COVID-19 management

A Saggam, K Limgaokar, S Borse… - Frontiers in …, 2021 - frontiersin.org
As the COVID-19 pandemic is progressing, the therapeutic gaps in conventional
management have highlighted the need for the integration of traditional knowledge systems …

[HTML][HTML] Disease-drug and drug-drug interaction in COVID-19: Risk and assessment

D Kumar, N Trivedi - Biomedicine & Pharmacotherapy, 2021 - Elsevier
COVID-19 is announced as a global pandemic in 2020. Its mortality and morbidity rate are
rapidly increasing, with limited medications. The emergent outbreak of COVID-19 prompted …

Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies

G Robinson, I Pineda-Torra, C Ciurtin… - The Journal of …, 2022 - Am Soc Clin Investig
Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic
diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus …

A review on potential of natural products in the management of COVID-19

R Chakravarti, R Singh, A Ghosh, D Dey, P Sharma… - RSC …, 2021 - pubs.rsc.org
At the end of 2019, a life threatening viral infection (COVID-19) caused by a novel
coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was …